R

Resmed

Cloud-connected medical devices and software platforms

Test Automation Engineer

Full-Time
No salary listed
Senior
Bachelor's
Remote in Germany
Remote
QA & TestingTest Automation Engineering

About the job

Requirements
  • A degree in Computer Science or Software Engineering, comparable technical training, or a comparable practical qualification.
  • Several years of practical experience in software testing, quality assurance, or software development.
  • Several years of practical experience in test automation and its integration into CI/CD pipelines.
  • Practical experience automating user interfaces, APIs, integrations, and regression tests with relevant frameworks and programming languages.
  • Confident use of test automation tools such as Playwright, Selenium, Appium, Cucumber, Postman, Bruno, RestAssured, or comparable technologies.
  • Confident programming or scripting with .NET, TypeScript, or comparable languages, and familiarity with C# environments.
  • Practical experience with TeamCity, GitHub Actions, or comparable CI/CD systems.
  • Ability to communicate complex technical and quality-related content confidently in German and English.
  • Drive sustainable quality improvements and take responsibility for their implementation.
  • Identify obstacles and quality risks early and develop viable recommendations with involved teams.
  • Communicate complex matters appropriately to different audiences and strengthen collaboration on quality issues and incidents.
  • Evaluate decisions based on effort, risk, quality gains, compliance, and product value.
Responsibilities
  • Develop, implement, and maintain automated tests for functionality, regression, user interfaces, APIs, integrations, performance, security, and load.
  • Select suitable test automation frameworks, tools, and patterns together with the development team and ensure their sustainable use.
  • Integrate automated tests into CI/CD pipelines and continuously improve the stability, maintainability, and informative value of test results.
  • Analyze test results, defects, flakiness, performance problems, and quality risks, and support structured root-cause analysis.
  • Develop test strategies and quality approaches for team and project contexts, and ensure risk-based test coverage for features and interfaces.
  • Bring quality, testability, and automation considerations into architecture and design decisions, considering testability, quality, maintainability, observability, resilience, performance, and security.
  • Advise Software Engineering, Testing, Product Management, and adjacent functions on test strategy, test automation, and quality assurance, and support quality-related incidents.
  • Connect test results, defects, pipeline data, product feedback, and metrics to inform quality decisions and prioritize improvement measures.
  • Transfer knowledge through pairing, reviews, and mentoring, and introduce new methods and automation approaches to the team.
Desired Qualifications
  • ISTQB Advanced Level Test Automation Engineer certification or a comparable qualification.
  • Experience with BDD, Gherkin, or Specification by Example, as well as performance, security, load, or end-to-end testing.
  • Knowledge of healthcare requirements, regulated environments, or business-critical software.

About the company

R

Resmed

View
Website

ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1989

Get referred to Resmed

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 guidance shows 5%-7% revenue growth and 12%-14% core EPS growth.
  • MatrixCare closed September 1, 2026, freeing capital for higher-margin core businesses.
  • ResMed's connected network and Oura partnership expand diagnosis and PAP adoption funnels.

What critics are saying

  • Astral no-new-sales in fiscal 2027 removes $75 million revenue and damages trust.
  • KPMG exit and PwC onboarding increase reporting disruption risk before the next 10-Q.
  • Philips Respironics' U.S. return in 2027 can compress pricing and share quickly.

What makes Resmed unique

  • ResMed's cloud-connected AirSense platform locks in recurring resupply and adherence data.
  • Noctrix acquisition broadens ResMed beyond apnea into restless legs syndrome treatments.
  • MatrixCare sale and core-device focus sharpen execution around sleep, breathing, and home care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Holidays
  • Parental Leave
  • 401(k) Retirement Plan
  • Employee Assistance Program (EAP)

Growth & Insights and Company News

6 month growth

7%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Oct 23rd, 2026
ResMed launches AirTouch F40 mask in US, but analysts see only an incremental boost

ResMed has launched its AirTouch F40 CPAP mask in the US. The fabric-cushioned design connects to the company's myAir and AirView platforms and aims to improve comfort, adherence and fitting for obstructive sleep apnea patients. Existing AirFit F40 users can switch to the new ComfiSoft fabric cushion without a full refit. This could lift resupply activity and keep patients within ResMed's connected ecosystem. The launch looks incremental. Supply chain costs and the Astral ventilator remediation remain the main near-term risks, with a headwind expected in FY2027. From July to September 2026, ResMed retired 972,000 shares for $200 million. Analysts' narrative projects $6.6 billion in revenue and $1.9 billion in earnings by 2029.

GlobeNewswire
Oct 19th, 2026
Resmed launches AirTouch(TM) F40 full face fabric CPAP mask in the U.S.

Resmed launches AirTouch(TM) F40 full face fabric CPAP mask in the U.S. Latest addition to Resmed's growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choice. October 19, 2026 08:00 ET | Source: Resmed, Inc. SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40, the newest addition to its growing portfolio of fabric continuous positive airway pressure (CPAP) masks. Designed for people with obstructive sleep apnea (OSA) to provide greater comfort and choice in therapy[1], the AirTouch F40 helps address key factors that can influence long-term adherence. OSA is a growing health challenge, affecting more than one billion people worldwide.[2] In the U.S., an estimated 61 million people have OSA, a number projected to rise to nearly 77 million by 2050.[3] CPAP therapy remains the gold standard treatment for OSA[4], and for those on CPAP, mask comfort and fit can play an important role in how people stay engaged with therapy over time. AirTouch F40 brings Resmed's proprietary ComfiSoft(TM) fabric cushion to a minimalist design that is intended to adapt to a person's face as they move throughout the night. Because comfort preferences vary from person to person, expanding mask choice helps give people another option to meet their individual needs. The mask's wide fit range and intuitive design are also intended to make it easier for healthcare providers to help patients find a comfortable fit and support them throughout therapy. AirTouch F40 builds on Resmed's growing portfolio of fabric-based mask technology and reflects the company's commitment to delivering more personalized experiences that support patients throughout their therapy experience. Resmed has seen encouraging outcomes across its fabric mask portfolio, including a 6% increase in 90-day compliance among users of a fabric-cushioned mask compared with users of a silicone-cushioned mask.[5] "AirTouch F40 is one example of how we're continuing to redefine what's possible to create more comfortable and personalized therapy experiences," said Justin Leong, Chief Product Officer at Resmed. "By building on the success of AirFit F40(TM) and introducing a new fabric option, we're giving people greater flexibility to choose the mask that works best for them. That's the kind of innovation that can help more people start and stay on CPAP therapy." Key features of AirTouch F40 include: * Designed to fit and move with the user: AirTouch F40 is designed to fit 96% of people[6] with a minimalist design that adapts to the face as people move throughout the night. * Brings fabric comfort to the full-face experience: The ComfiSoft fabric cushion features soft, breathable, and moisture-wicking fabric[7] designed for comfort against the skin. * A familiar platform for existing AirFit F40 users: The interchangeable cushion allows current AirFit F40 users to try the fabric cushion without changing mask systems or being resized or refitted. Connected support throughout therapy AirTouch F40 is part of Resmed's connected sleep health platform, bringing together devices, digital tools and provider support to create a more connected therapy experience and help people stay engaged over time. Through myAir(TM), Resmed's patient engagement app, people can track their therapy progress, access personalized guidance and receive ongoing support throughout their therapy experience. This includes upcoming features such as Equipment Care, a tool that is designed to encourage patients to take action and stay engaged in managing their CPAP equipment. Healthcare providers can use AirView(TM), Resmed's remote monitoring platform, to view therapy insights and support patients between appointments. When used alongside AirView, myAir has been shown to improve therapy compliance from 70% to 87%.[8] AirTouch F40 will be available in the U.S. beginning October 28, 2026. For more information, visit https://www.resmed.com/en-us/health-professionals/campaigns/airtouch-f40/ About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed. For Investors [1] Resmed external crossover study comparing AirTouch F40 mask against other Resmed and third-party masks. n=36. Data on file, ID: A5768170. [2] Benjafield AV, et al. Lancet Respir Med. 2019 Aug; 7(8):687-698. [3] Boers E, et al. Lancet Respir Med. 2025;13(12):1078-1086. [4] Patil SP et al. J Clin Sleep Med. 2019 Feb 15;15(2):301-334. [5] Resmed analysis of 90-day PAP compliance among U.S. patients using AirView(TM) and myAir(TM), comparing AirTouch(TM) N30i and AirFit(TM) N30i. Data on file, ID: A5707362. [6] Internal Resmed analysis of projected cushion fit per region. Data on file, ID: A5756043. [7] Resmed internal testing of the moisture-wicking properties of fabric. Data on file, ID: A5636924. [8] Malhotra et al., CHEST. 2018; 153(4): 843-850.

HEM News
Oct 19th, 2026
Resmed invests in Eight Sleep and links myAir data to its smart mattress app

Eight Sleep and Resmed have formed a partnership to help people in the US and Australia better understand their sleep health. Resmed has also invested in Eight Sleep; the source gives no amount. Users of a Resmed PAP device with the myAir app and an Eight Sleep Pod can now connect their myAir insights to the Eight Sleep app. With the user's permission, the data appears alongside Eight Sleep metrics, so members can track it over time. The integration is live in both countries. The companies plan to expand to more markets. "This collaboration allows Eight Sleep members who use a Resmed PAP device with the myAir app to gain broader insights into their sleep health," said Matteo Franceschetti, co-founder and chief executive officer of Eight Sleep.

Barchart
Oct 15th, 2026
ResMed's quarterly earnings preview: what you need to know.

ResMed's quarterly earnings preview: what you need to know. Follow this Author ResMed Inc. (RMD) is a global health technology company focused on sleep and breathing health, developing cloud-connected medical devices, masks, and digital health solutions for conditions such as sleep apnea and chronic respiratory diseases, alongside software for residential and out-of-hospital care. Headquartered in San Diego, California, ResMed serves customers in more than 140 countries and has a market cap of around $33.1 billion. The company is slated to announce its first-quarter fiscal year 2027 results on Thursday, Oct. 29, after the market closes. Ahead of the event, analysts expect RMD to report an adjusted EPS of $2.70, up 5.9% from $2.55 in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in each of the last four quarters. For fiscal 2027, analysts expect RMD to report a profit of $12.07 per share, representing an 8.1% increase from $11.17 per share in fiscal 2026. Furthermore, its EPS is expected to grow 8.6% year-over-year to $13.11 in fiscal 2028. Shares of ResMed have decreased 12.9% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 16.2% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 22.2% return over the same period. ResMed shares have faced pressure in 2026 primarily due to concerns over slower near-term growth and increasing competitive risks. The pressure intensified in August after ResMed issued weaker-than-expected fiscal 2027 revenue guidance of $5.75 billion to $5.85 billion, partly reflecting a $75 million revenue headwind from a safety-related suspension of Astral ventilator sales. Meanwhile, for the last reported quarter, that is in Q4 FY2026, ResMed's revenue increased 9% year-over-year (YOY) to $1.5 billion, while non-GAAP EPS increased 16% to $2.95. For the full fiscal year ended June 30, ResMed reported revenue of $5.7 billion, up 10% YOY, and non-GAAP EPS rose 17% to $11.17. Wall Street analysts are moderately optimistic about RMD's stock, with a "Moderate Buy" rating overall. Among 21 analysts covering the stock, eight recommend "Strong Buy," one suggests a "Moderate Buy," 11 propose "Hold," and one advises a "Strong Sell" rating. The mean price target for RMD is $238.80, implying just 1.5% upside from the current levels. On the date of publication, Subhasree Kar did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. More News from Barchart

MarketBeat
Oct 8th, 2026
ResMed (NYSE:RMD) stock: insider Michael Farrell sells 4,991 shares.

ResMed (NYSE:RMD) stock: insider Michael Farrell sells 4,991 shares. October 8, 2026 Key points. * CEO Michael Farrell sold 4,991 ResMed shares at an average price of $226.33, generating approximately $1.13 million. The transaction reduced his holdings by 1.03% and was conducted under a pre-arranged Rule 10b5-1 trading plan. * ResMed reported quarterly EPS of $2.95, exceeding estimates of $2.89, while revenue reached $1.46 billion and increased 8.6% year over year. The company also raised its quarterly dividend to $0.66, equivalent to a 1.2% yield. * Analyst sentiment is mixed, with seven Buy ratings and nine Hold ratings, producing a consensus rating of "Hold" and an average price target of $241.69. Shares recently traded near $226.52, with a 12-month range of $180.26 to $284.05. * MarketBeat previews the top five stocks to own by November 1st. ResMed Inc. (NYSE:RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the firm's stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $226.33, for a total value of $1,129,613.03. Following the completion of the transaction, the chief executive officer owned 479,803 shares in the company, valued at $108,593,812.99. The trade was a 1.03% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. ResMed price performance. Shares of NYSE:RMD traded up $0.54 during midday trading on Thursday, hitting $226.52. The company's stock had a trading volume of 651,064 shares, compared to its average volume of 1,299,688. The company has a market cap of $31.86 billion, a P/E ratio of 21.72, a price-to-earnings-growth ratio of 1.39 and a beta of 0.75. ResMed Inc. has a 12-month low of $180.26 and a 12-month high of $284.05. The business's 50 day simple moving average is $224.88 and its 200 day simple moving average is $213.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.06. The company had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.46 billion. ResMed had a net margin of 26.94% and a return on equity of 25.58%. ResMed's revenue was up 8.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.55 EPS. On average, analysts forecast that ResMed Inc. will post 12.07 EPS for the current year. ResMed increases dividend. The business also recently declared a quarterly dividend, which was paid on Thursday, September 24th. Stockholders of record on Thursday, August 20th were given a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.2%. This is a boost from ResMed's previous quarterly dividend of $0.60. The ex-dividend date was Thursday, August 20th. ResMed's dividend payout ratio (DPR) is currently 25.31%. Institutional investors weigh in on ResMed. Institutional investors have recently modified their holdings of the company. Kera Capital Partners Inc. raised its stake in shares of ResMed by 6.6% in the fourth quarter. Kera Capital Partners Inc. now owns 841 shares of the medical equipment provider's stock valued at $217,000 after acquiring an additional 52 shares in the last quarter. Andina Capital Management LLC boosted its holdings in ResMed by 2.9% in the fourth quarter. Andina Capital Management LLC now owns 1,988 shares of the medical equipment provider's stock valued at $479,000 after purchasing an additional 56 shares during the period. Turtle Creek Wealth Advisors LLC grew its stake in ResMed by 6.2% during the 1st quarter. Turtle Creek Wealth Advisors LLC now owns 994 shares of the medical equipment provider's stock worth $223,000 after purchasing an additional 58 shares in the last quarter. Meridian Management Co. grew its stake in ResMed by 0.6% during the 1st quarter. Meridian Management Co. now owns 11,332 shares of the medical equipment provider's stock worth $2,544,000 after purchasing an additional 70 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its holdings in ResMed by 1.3% during the 1st quarter. Glenmede Trust Co. NA now owns 5,479 shares of the medical equipment provider's stock worth $1,230,000 after purchasing an additional 71 shares during the period. 54.98% of the stock is owned by institutional investors and hedge funds. Analysts set new price targets. RMD has been the topic of a number of analyst reports. Mizuho reduced their price objective on ResMed from $235.00 to $220.00 and set an "outperform" rating on the stock in a research report on Wednesday, July 15th. Citigroup reaffirmed a "neutral" rating on shares of ResMed in a research note on Thursday, September 10th. KeyCorp lifted their price target on ResMed from $255.00 to $267.00 and gave the stock an "overweight" rating in a report on Monday, August 31st. Robert W. Baird set a $213.00 price objective on shares of ResMed in a report on Friday, August 7th. Finally, UBS Group restated a "buy" rating and set a $300.00 price objective on shares of ResMed in a research report on Tuesday, July 21st. Seven investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, ResMed currently has an average rating of "Hold" and a consensus price target of $241.69. Discover more Financial News Subscription Live News Feed Stock Profit Calculator About ResMed. ResMed Inc NYSE: RMD develops, manufactures and distributes medical equipment and digital health solutions for sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its products include continuous positive airway pressure (CPAP), bilevel and other noninvasive ventilation devices, as well as masks, humidifiers, accessories and diagnostic equipment. The company also provides cloud-connected software and digital health services that support patient monitoring, therapy management and communication among patients, clinicians and care providers. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider ResMed, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ResMed wasn't on the list. While ResMed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets. Continue following MarketBeat